论文部分内容阅读
目的:讨论帕罗西汀+心理疗法治疗精神分裂症后抑郁的临床效果.方法:2020年1月-2021年1月,将60例精神分裂症后抑郁患者随机分为对照组与研究组各30例,对照组实施帕罗西汀治疗,研究组实施帕罗西汀+心理疗法治疗,观察指标:疗效、HAMD评分、BPRS评分、SDSS评分及ADL评分.结果:研究组疗效总有效率的96.67％明显高于对照组的70％,P＜0.05.HAMD评分及BPRS评分治疗前组间统计学差异并不显著,P＞0.05;治疗后组间统计学差异明显,表现为治疗4周及8周后研究组HAMD评分及BPRS评分下降程度均明显优于对照组,P＜0.05.SDSS评分及ADL评分治疗前组间统计学差异并不显著,P＞0.05;治疗后组间统计学差异明显,表现为治疗后研究组SDSS评分明显低于对照组,ADL评分明显高于对照组,P＜0.05.结论:帕罗西汀+心理疗法治疗精神分裂症后抑郁病症的疗效明显,利于显著改善患者的抑郁情绪及精神状态,减轻其社会功能缺陷,提高日常生活水平,值得推广.“,”Objective: to discuss the clinical effect of paroxetine plus psychotherapy in the treatment of post schizophrenia depression. Methods: from January 2020 to January 2021, 60 patients with post schizophrenic depression were randomly divided into control group and study group, 30 cases in each group. The control group was treated with paroxetine, while the study group was treated with paroxetine plus psychotherapy. Results: 96.67％ of the total effective rate of the study group was significantly higher than 70％ of the control group, P ＜ 0.05. There was no significant difference in HAMD score and BPRS score between the two groups before treatment (P ＞ 0.05); After 4 and 8 weeks of treatment, the HAMD score and BPRS score of the study group were significantly better than those of the control group, P ＜0.05. There was no significant difference in SDSS score and ADL score between the two groups before treatment (P ＞ 0.05); After treatment, the SDSS score of the study group was significantly lower than that of the control group, ADL score was significantly higher than that of the control group, P ＜ 0.05. Conclusion: Paroxetine plus psychotherapy is effective in the treatment of post schizophrenic depression, which can significantly improve the depression and mental state of patients, reduce their social function defects, and improve their daily living standards, which is worthy of promotion.